--- title: "Tango Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286350666.md" datetime: "2026-05-14T03:21:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286350666.md) - [en](https://longbridge.com/en/news/286350666.md) - [zh-HK](https://longbridge.com/zh-HK/news/286350666.md) --- # Tango Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 578.09 K. EPS: As of FY2026 Q1, the actual value is USD -0.32, missing the estimate of USD -0.3142. EBIT: As of FY2026 Q1, the actual value is USD -50.95 M. Tango Therapeutics, Inc. operates as a single segment, Oncology . #### Segment Revenue - **Collaboration Revenue**: Tango Therapeutics, Inc. reported $0 in collaboration revenue for the three months ended March 31, 2026, a decrease from $5.4 million for the same period in 2025 . This change was attributed to the recognition of all remaining deferred revenue from the Gilead Agreement in 2025 after the collaboration agreement was truncated . #### Operational Metrics - **Research and Development Expenses**: Research and development expenses were $33.5 million for the three months ended March 31, 2026, down from $36.4 million for the same period in 2025, representing a $2.9 million decrease . This decrease was primarily due to a $1.1 million reduction from the discontinuation of the TNG908 clinical program, a $1.8 million decrease in TNG961 development costs, and lower discovery program, personnel-related, and facilities-related expenses . These reductions were partially offset by increased spending on the vopimetostat and TNG456 clinical programs . - vopimetostat direct program expenses: $9.332 million (2026) vs $5.461 million (2025) . - TNG456 direct program expenses: $2.063 million (2026) vs $1.324 million (2025) . - TNG260 direct program expenses: $2.009 million (2026) vs $1.730 million (2025) . - TNG961 direct program expenses: $0.408 million (2026) vs $2.221 million (2025) . - TNG908 direct program expenses: $0.581 million (2026) vs $1.712 million (2025) . - Discovery direct program expenses: $1.872 million (2026) vs $4.679 million (2025) . - Personnel-related expenses - R&D: $12.931 million (2026) vs $13.850 million (2025) . - Facilities and other related expenses - R&D: $4.338 million (2026) vs $5.465 million (2025) . - **General and Administrative Expenses**: General and administrative expenses increased to $15.2 million for the three months ended March 31, 2026, from $11.5 million for the same period in 2025, an increase of $3.8 million . This was primarily due to higher personnel-related costs, including share-based compensation expense . - **Total Operating Expenses**: Total operating expenses were $48.769 million for the three months ended March 31, 2026, compared to $47.922 million for the same period in 2025 . - **Loss from Operations**: The loss from operations was - $48.769 million for the three months ended March 31, 2026, compared to - $42.530 million for the same period in 2025 . - **Interest Income**: Interest income increased to $2.2 million for the three months ended March 31, 2026, from $1.6 million for the same period in 2025, mainly due to a higher marketable securities balance . - **Other Income, Net**: Other income, net, remained constant at $1.1 million for both three-month periods ended March 31, 2026 and 2025, primarily from accretion from investments . - **Net Loss**: The net loss was - $45.5 million for the three months ended March 31, 2026, compared to - $39.9 million for the same period in 2025 . - **Accumulated Deficit**: The accumulated deficit was - $648.7 million as of March 31, 2026 . #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $44.4 million for the three months ended March 31, 2026, compared to - $41.7 million for the same period in 2025, primarily due to an increased net loss and higher operating expenses . - **Net Cash Provided by Investing Activities**: Net cash provided by investing activities was $9.6 million for the three months ended March 31, 2026, down from $30.6 million for the same period in 2025 . This was mainly due to a decrease in sales and maturities of marketable securities and an increase in purchases of marketable securities . - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities significantly increased to $79.8 million for the three months ended March 31, 2026, from less than $0.1 million for the same period in 2025 . This increase was primarily driven by $62.8 million in net proceeds from at-the-market stock offerings and $17.6 million from stock option exercises . #### Unique Metrics - **Cash, Cash Equivalents, and Marketable Securities**: As of March 31, 2026, Tango Therapeutics, Inc. held $379.8 million in cash, cash equivalents, and marketable securities . - **Total Funding Raised**: Through March 31, 2026, the company raised an aggregate of $1.2 billion in funding, comprising $921.4 million from equity financings and $237.1 million from collaboration with Gilead . #### Future Outlook and Strategy Management expects Tango Therapeutics, Inc.’s existing cash, cash equivalents, and marketable securities of $379.8 million as of March 31, 2026, to fund operating expenses and capital expenditure requirements into 2028 . The company anticipates continued significant operating losses and increasing expenses as product candidates advance through development . Tango Therapeutics, Inc. plans to finance operations through equity offerings, debt financings, and potential collaboration agreements, though profitability is not assured . ### Related Stocks - [TNGX.US](https://longbridge.com/en/quote/TNGX.US.md) ## Related News & Research - [Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX](https://longbridge.com/en/news/286550878.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Financial year ending 31 March 2026 reports final results.](https://longbridge.com/en/news/287166907.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md)